Connect Biopharma Holdings Limited - ADR

The momentum for this stock is not very good. Connect Biopharma Holdings Limited - ADR is not a good value stock. Connect Biopharma Holdings Limited - ADR is not a good growth stock. Connect Biopharma Holdings Limited - ADR is not very popular among insiders. Tradey thinks it is not wise to invest in Connect Biopharma Holdings Limited - ADR.
Log in to see more information.

News

Connect Biopharma Welcomes New Finance VP
Connect Biopharma Welcomes New Finance VP

TipRanks Financial Blog Connect Biopharma Holdings (CNTB) has released an update. Connect Biopharma Holdings Limited has announced an executive shuffle with the appointment of Lisa Peraza ...\n more…

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Globe Newswire Announced new U.S.-based leadership with the appointment of Barry Quart, Pharm.D. as Chief Executive Officer (CEO) and David Szekeres as PresidentConnect's new management is currently evaluating the...\n more…

Connect Biopharma Executives Transition to New Roles
Connect Biopharma Executives Transition to New Roles

TipRanks Financial Blog Connect Biopharma Holdings (CNTB) has released an update. Connect Biopharma Holdings Limited has announced the transition of two key figures, Dr. Zheng Wei and Dr. ...\n more…

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Globe Newswire SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage...\n more…

Leadership Expertise and Strategic Focus Poise Connect Biopharma for Commercial Success
Leadership Expertise and Strategic Focus Poise Connect Biopharma for Commercial Success

TipRanks Financial Blog In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Connect Biopharma Holdings (CNTB - Research Report), with ...\n more…

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage...\n more…